title: Neuropeptide Y Y1 receptor polymorphism as a prognostic predictor in Japanese patients with IgA nephropathy.
abstract: BACKGROUND
  Neuropeptide Y exhibits a vasoconstricting action and regulates systemic blood pressure as well as noradrenalin. There are 5 types of NPY receptors, Y1 - Y5, which were introduced by pharmacological differences. Recently, a single point mutation in the first intron of the NPY Y1 receptor (NPYY1R) was reported.
  
  
  METHODS
  In this study, we investigated the relationship between NPYY1R gene polymorphism and clinical characteristics in patients with IgA nephropathy using polymerase chain reaction and restriction fragment length polymorphism analysis.
  
  
  RESULTS
  Distribution of the NPYY1R genotypes which were defined as YY, Yy and yy genotypes, did not differ between 60 normal control subjects and 68 patients with IgA nephropathy (15 : 36 : 9 versus 21 : 40 : 7, respectively). In IgA nephropathy patients, the incidence of hypertension and the rate of urinary protein excretion were slightly higher in the non-YY genotype than in the YY genotype group (23% versus 5% and 1.1 +/- 1.2 versus 0.6 +/- 0.4 g/24 h, p = 0.09 and p = 0.05, respectively). The reciprocal of the serum creatinine level was estimated to determine the deterioration in renal function during follow-up after the renal biopsy. The level was lower in the non-YY genotype than in the YY genotype group (-0.002 +/- 0.064 vs 0.033 +/- 0.053/month, respectively, p < 0.01). Multiple regression analysis for the reciprocal of the serum creatinine level revealed that the NPYY1R genotype was an effective variable (p < 0.01).
  
  
  CONCLUSIONS
  In conclusion, we propose that the NPYY1R gene polymorphism may be a novel prognostic predictor in patients with IgA nephropathy.
authors.affiliation: Second Department of Internal Medicine, Kochi Medical School, Nankoku, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Morita
authors.forename: T
authors.initials: T
authors.lastname: Suehiro
authors.forename: K
authors.initials: K
authors.lastname: Tahara
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Y
authors.initials: Y
authors.lastname: Nakauchi
authors.forename: S
authors.initials: S
authors.lastname: Makino
authors.forename: K
authors.initials: K
authors.lastname: Nishiya
authors.forename: K
authors.initials: K
authors.lastname: Hashimoto
mesh_terms: D000328:Adult; D003404:Creatinine / Q000097:blood; D005260:Female; D005838:Genotype; D005922:Glomerulonephritis, IGA / Q000175:diagnosis* / Q000235:genetics; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011379:Prognosis; D011507:Proteinuria; D017476:Receptors, Neuropeptide Y / Q000235:genetics*
chemical_list: D017476:Receptors, Neuropeptide Y; D003404:Creatinine